Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.1 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -9.59%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.13 per share when it actually produced a loss of $0.12, delivering a surprise of +7.69%.Over the last four qua ...

SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced the appointment of R. LaDuane Clifton as Chief Financial Officer (CFO). “As Transpire Bio continues to progress from a clinical-stage to commercial-stage biopharmaceutical company, we are aligning our leadership structure to support the next phase of our growth,” said Dr. Xian-Ming Zeng, Chi ...

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Phreesia, Inc. (NYSE: PHR) regarding possible recovery of losses under federal securities laws following a significant stock price decline after the company's earnings call [1][1]. Investigation Background - On December 9, 2025, Phreesia's stock price dropped approximately 25% after the company updated its fiscal 2026 revenue guidance during its third quarter earnings call [1][1]. - The investigation focuses on whether Phreesia's executive officers complied with federal securities laws, which may have implications for investor losses [1][1]. Company Profile - Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with multiple offices across the United States, specializing in securities class action lawsuits and representing both individual and institutional investors [1][1]. - The firm has a notable track record, having recovered approximately $90.725 million for clients in cases where it served as lead or co-lead counsel, and has been recognized as a top plaintiffs' securities law firm in the U.S. [1][1].

Core Points - PepGen Inc. announced an underwritten public offering of common stock and pre-funded warrants, leading to a 112.4% increase in its share price to $5.65 in pre-market trading [1] - Other notable stock movements include OFA Group rising 49.6% to $1.99 due to a partnership announcement, and WORK Medical Technology Group increasing 50.4% to $0.1693 after a significant drop the previous day [5] - Lithium Americas Corp. gained 36.8% to $8.21 following reports of Trump officials seeking an equity stake in the company related to a $2.26 billion loan renegotiation [5] Gainers - Immuneering Corporation rose 30% to $12.00 after pricing a $175 million public offering and a $25 million private placement [5] - 22nd Century Group, Inc. gained 37.7% to $2.08 after securing $9.5 million from an insurance claim settlement [5] - ClearPoint Neuro, Inc. increased by 12.8% to $21.76 after a previous gain of 58% [5] Losers - SeaStar Medical Holding Corporation dipped 43.3% to $0.7035 following a recommendation to continue a pivotal trial [5] - Cemtrex, Inc. shares fell 27.7% to $0.4530 after approving a 1-for-15 reverse stock split [5] - Lunai Bioworks Inc. declined 25.3% to $0.1290 after announcing a 10-for-1 reverse stock split [5]

Core Insights - Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is highlighted as a promising investment opportunity in the biotech sector, particularly due to its recent positive data regarding MIPLYFFA® (arimoclomol) for Niemann-Pick Disease Type C [1][2] - The company focuses on developing therapies for rare diseases, specifically targeting conditions with limited treatment options, including Idiopathic Hypersomnia and Urea Cycle Disorders [2] Group 1 - On September 4, Zevra Therapeutics announced new data supporting the effectiveness of MIPLYFFA® in treating Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism [1] - A pre-specified analysis indicated that patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression [2] - Zevra Therapeutics is a commercial-stage company with a product portfolio that emphasizes rare neurological and sleep conditions [2]

U.S. Stock Market Performance - U.S. stocks traded higher, with the Dow Jones index gaining over 400 points, closing up 0.97% at 44,888.04 [1] - The NASDAQ rose 0.14% to 21,711.19, and the S&P 500 increased by 0.24% to 6,461.26 [1] Sector Performance - Health care shares increased by 1% on Wednesday [1] - Utilities stocks fell by 0.7% during the same trading session [1] Company Earnings Reports - Performance Food Group Company (PFGC) reported fourth-quarter adjusted EPS of $1.55, exceeding the analyst consensus estimate of $1.45 [2] - Quarterly sales reached $16.938 billion, surpassing the expected $16.860 billion, reflecting an 11.5% year-over-year increase [2] Commodity Market Updates - Oil prices decreased by 1% to $62.57, while gold prices increased by 0.4% to $3,412.90 [4] - Silver rose by 1.4% to $38.545, whereas copper fell by 0.3% to $4.5115 [4] European Market Performance - European shares showed positive movement, with the eurozone's STOXX 600 rising by 0.52% [5] - Spain's IBEX 35 Index increased by 0.95%, London's FTSE 100 rose by 0.15%, Germany's DAX 40 gained 0.74%, and France's CAC 40 rose by 0.73% [5] Asian Market Performance - Asian markets closed higher, with Japan's Nikkei 225 gaining 1.30%, Hong Kong's Hang Seng up by 2.58%, China's Shanghai Composite increasing by 0.48%, and India's BSE Sensex rising by 0.38% [6] Notable Stock Movements - Bolt Projects Holdings, Inc. (BSLK) shares surged 147% to $5.38 following a year-over-year increase in second-quarter financial results [8] - Sapiens International Corporation N.V. (SPNS) shares rose 44% to $42.54 after Advent agreed to acquire the company in a $2.5 billion deal [8] - WEBTOON Entertainment Inc. (WBTN) shares increased by 80% to $16.88 after announcing a partnership with Disney [8] - Zevra Therapeutics, Inc. (ZVRA) shares dropped 22% to $9.15 after second-quarter results [8] - KinderCare Learning Companies, Inc. (KLC) shares fell 16% to $8.20 after missing second-quarter earnings estimates [8] - ProFrac Holding Corp. (ACDC) shares decreased by 39% to $3.8550 after pricing a $75 million stock offering at $4 per share [8]

Industry Overview - The uncertainty surrounding tariffs and trade measures has impacted economic growth, with President Trump threatening to impose tariffs as high as 200% on pharmaceutical imports to encourage domestic production [1] - Despite these threats, the biotech sector has remained stable, with many global pharmaceutical companies already investing in domestic manufacturing [1] Current Trends - The Zacks Medical-Drugs industry is showing promising trends due to positive pipeline and regulatory developments [2] - Key areas of innovation include rare diseases, next-generation oncology treatments, obesity, immunology, and neuroscience, attracting significant investor interest [3] M&A Activity - M&A activity in the sector remains healthy, indicating growth potential for companies like Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics, and Larimar Therapeutics [3] Industry Characteristics - The Zacks Medical-Drugs industry consists of small to medium-sized drug companies that produce medicines for human and veterinary use, often relying on collaboration payments for revenue [4] Factors Influencing Future Growth - The success of key pipeline candidates in clinical studies can significantly impact stock prices, with successful innovations acting as catalysts [5] - Strong collaboration with larger drugmakers is a positive indicator for small pharma companies, especially when equity investments are involved [6] - Investment in technology and personalized medicine is crucial for smaller companies to thrive in a changing healthcare landscape [7] Performance Metrics - The Zacks Medical-Drugs industry currently holds a Zacks Industry Rank of 96, placing it in the top 39% of 245 Zacks industries, indicating strong prospects [9] - Year-to-date, the industry has risen 5.6%, outperforming the Zacks Medical sector, which has decreased by 2.9%, while slightly underperforming the S&P 500, which has risen by 6.9% [11] Valuation - The industry is currently trading at a trailing 12-month price-to-sales ratio of 2.32, compared to the S&P 500's 5.66 and the Zacks Medical sector's 2.37 [12] Company Highlights - **Catalyst Pharmaceuticals**: Lead drug Firdapse shows strong demand; stock has risen 0.4% this year; earnings estimate for 2025 increased from $2.23 to $2.25 [16][17] - **Theravance Biopharma**: Strong sales from Yupelri; stock has risen 22.6% this year; earnings estimate for 2025 declined from 3 cents to 1 cent [20][21] - **Larimar Therapeutics**: Developing nomlabofusp for Friedreich's ataxia; stock has declined 18.3% this year; loss estimate for 2025 narrowed from $1.90 to $1.89 [24][25] - **Zevra Therapeutics**: Early adoption of Miplyffa exceeds expectations; stock has risen 53.4% this year; earnings estimate for 2025 increased from 31 cents to 76 cents [28][29] - **Aldeyra Therapeutics**: Focused on RASP modulators; stock has declined 0.4% this year; loss estimate for 2025 narrowed from $1.03 to 90 cents [31][32]

Core Viewpoint - Zevra Therapeutics is urging stockholders to support its current board and management team in the upcoming election, emphasizing their successful track record and strategic direction, while opposing the influence of a minority stockholder seeking to replace qualified directors without a clear plan [1][3][30]. Group 1: Company Performance and Strategy - Zevra has achieved total stockholder returns of 54.8% since the appointment of CEO Neil McFarlane in October 2023, outperforming the biotech sector and the Russell 2000 [8][42]. - The company has launched two rare disease therapies, MIPLYFFA and OLPRUVA, and has expanded its commercial capabilities significantly [20][24]. - A comprehensive five-year strategic plan has been established to drive long-term growth, focusing on commercial excellence, pipeline innovation, talent development, and corporate foundation [7][16]. Group 2: Board and Management Recommendations - The board recommends stockholders vote "FOR" the re-election of independent directors Wendy L. Dixon, Ph.D., and Tamara A. Favorito, who bring extensive experience and have contributed to the company's strategic goals [2][11][29]. - The board emphasizes that seven of the eight current directors have joined since 2023, reflecting a proactive refreshment aimed at enhancing governance and oversight [4][27]. Group 3: Opposition to Minority Stockholder Influence - Daniel J. Mangless, a minority stockholder with 2.8% ownership, is attempting to replace two directors without providing a clear strategy for improving the company [4][19][30]. - The board expresses concerns that Mangless' nominees lack the necessary expertise and could disrupt the company's ongoing progress and strategic execution [12][36]. - The board highlights the potential risks associated with electing Mangless' nominees, citing their previous records of stockholder value destruction [9][41].

Core Insights - Zevra Therapeutics, Inc. has published significant findings regarding the mechanism of action of its therapy MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC), highlighting its potential to address the underlying pathology of the disease [1][2][3] Group 1: Mechanism of Action - The publication details how arimoclomol enhances the translocation of translation factors EB and E3 (TFEB & TFE3) from the cytosol to the nucleus, initiating a cascade that upregulates coordinated lysosomal expression and regulation (CLEAR) genes, including NPC1 [2] - Increased expression of CLEAR genes leads to higher NPC1 protein levels in lysosomes, improving cholesterol trafficking and correlating with better neurological behaviors in animal models [2] Group 2: Clinical Significance - MIPLYFFA, approved by the U.S. FDA on September 20, 2024, is indicated for use in combination with miglustat for treating neurological manifestations of NPC in patients aged 2 years and older [3][4] - In a pivotal phase 3 trial, MIPLYFFA demonstrated the ability to halt disease progression compared to placebo, as measured by the NPC Clinical Severity Scale [3] Group 3: Safety Information - Common adverse reactions reported in clinical trials include upper respiratory tract infection, diarrhea, and decreased weight, with hypersensitivity reactions such as urticaria and angioedema noted in some patients [5][8][9] - MIPLYFFA may cause increased serum creatinine levels without affecting glomerular function, primarily occurring within the first month of treatment [7] Group 4: Company Overview - Zevra Therapeutics focuses on developing therapies for rare diseases, aiming to create transformational treatments for conditions with limited or no options [13] - The company employs data-driven strategies to navigate complex drug development challenges, striving to make new therapies accessible to the rare disease community [13]

Core Insights - Zevra Therapeutics, Inc. has successfully closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $150 million, enhancing its financial flexibility for strategic priorities [1][2] Financial Performance - As of March 31, 2025, Zevra reported available unaudited cash, cash equivalents, and investments totaling $68.7 million. After the sale of the PRV, net cash proceeds of $148.3 million will increase total cash, cash equivalents, and investments to $217.0 million [3] Company Overview - Zevra Therapeutics is a commercial-stage company focused on developing therapies for rare diseases with limited or no treatment options, aiming to bring life-changing therapeutics to patients [4]